IDO1 and Alzheimer disease: Clinical and preclinical evidence increasingly suggests that therapy focusing on Trp metabolism through probiotics, Trp supplementation, or IDO1 inhibitors is a viable strategy for rebalancing the GBA and modulating neuroinflammation in early AD.